Results 41 to 50 of about 76,053 (241)

Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC) [PDF]

, 2013
Management of metastatic colorectal cancer requires a multimodal approach and must be performed by an experienced, multidisciplinary expert team. The optimal choice of the individual treatment modality, according to disease localization and extent, tumor
BASSO, ENRICO, CARUSO, DAVIDE, EVANGELISTA, SALVATORE, Foteini Vakiarou, G. Rinaldi, L. Bianchi, Lo Russo, Giuseppe, PAPA, ANSELMO, Perrone-congedi, Francesca, PRETE, ALESSANDRA ANNA, ROSSI, Luigi, SPINELLI, GIAN PAOLO, Stati, Valeria, TOMAO, SILVERIO, VERRICO, MONICA, ZORATTO, federica   +15 more
core   +1 more source

The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis

BMC Cancer, 2021
Background The role of capecitabine in neoadjuvant and adjuvant chemotherapy for early-stage triple-negative breast cancer (TNBC) is highly controversial.
Xingfa Huo, Jinming Li, Fuxing Zhao, Dengfeng Ren, Raees Ahmad, Xinyue Yuan, Feng Du, Jiuda Zhao   +7 more
doaj   +1 more source

Complex Chromosome-Positive Acute Myelogenous Leukemia Identified 16 Months following the Completion of Capecitabine Chemotherapy for Early-Stage Colon Cancer

Case Reports in Oncology, 2021
Capecitabine is an oral chemotherapy that is used to treat several cancer types, including breast, gastrointestinal, hepatobiliary, and ovarian. The use of antimetabolites in cancer therapy has generally not been associated with leukemogenesis.
Sureerat Jaruhathai, Uraree Phornvoranunt, Waran Wannasirikul   +2 more
doaj   +1 more source

Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients. Meta-regression analysis of randomized trials [PDF]

, 2011
Background: Although the addition of bevacizumab significantly improves the efficacy of chemotherapy for advanced breast cancer, regulatory concerns still exist with regard to the magnitude of the benefits and the overall safety profile.
Aapro M., Bria E., Carlini P., Cognetti F., Cuppone F., Fabi A., Ferretti G., Giannarelli D., Milella M., Nistico C., Papaldo P., Puglisi F., Russillo M., Sperduti I., Vaccaro V.   +14 more
core   +3 more sources

Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis

CPT: Pharmacometrics & Systems Pharmacology, 2019
Capecitabine is an oral prodrug of the anticancer drug 5‐fluorouracil (5‐FU). The primary aim of this study was to develop a pharmacokinetic model for capecitabine and its metabolites, 5′‐deoxy‐5‐fluorocytidine (dFCR), 5′‐deoxy‐5‐fluorouridine (dFUR), 5 ...
Bart A.W. Jacobs, Maarten J. Deenen, Markus Joerger, Hilde Rosing, Niels deVries, Didier Meulendijks, Annemieke Cats, Jos H. Beijnen, Jan H.M. Schellens, Alwin D.R. Huitema   +9 more
doaj   +1 more source

Preoperative chemoradiotherapy with capecitabine and triweekly oxaliplatin versus capecitabine monotherapy for locally advanced rectal cancer: a propensity-score matched study

BMC Cancer, 2022
Background Distant metastasis has been the main failure pattern for locoregionally advanced rectal cancer (LARC) patients, and intensified neoadjuvant chemotherapy has become a popular research topic.
Anchuan Li, Tingxuan Huang, Rong Zheng, Pan Chi, Zhihua Li, Xiaozhong Wang, Benhua Xu   +6 more
doaj   +1 more source

Epidemiology and natural history of central venous access device use and infusion pump function in the NO16966 trial [PDF]

, 2014
Background: Central venous access devices in fluoropyrimidine therapy are associated with complications; however, reliable data are lacking regarding their natural history, associated complications and infusion pump performance in patients with ...
A Surov, AA Martoni, C Araújo, C Twelves, D Fagnani, D Haller, DC McGee, DZ Xiang, E Chu, E Chu, E McKenna, E Van Cutsem, EA Poplin, EB Lamont, F Ng, G Perrocheau, H-J Schmoll, I Kriegel, J Cassidy, J Cassidy, J Kawamura, J Shen-Gunther, L Cavanna, L Garrison, LB Saltz, M Gann Jr, M Karthaus, M Verso, M W Saif, MM Beckers, N Barbetakis, N Starling, P Debourdeau, R Biffi, S Lee, T Cartwright, T Conroy, The Meta-Analysis Group In Cancer, W Saber, W Scheithauer, W Sun, Y Inaba   +41 more
core   +2 more sources

Randomized controlled trial on the efficacy of topical urea-based cream in preventing capecitabine-associated hand-foot syndrome

BMC Cancer
Background Hand-foot syndrome (HFS) is a common adverse event of capecitabine causing treatment modifications. Topical urea cream can reduce sorafenib-induced hand-foot skin reaction. However, its benefit in preventing capecitabine-associated HFS was not
Concord Wongkraisri, Kriengkrai Chusuwanrak, Apirom Laocharoenkeat, Leena Chularojanamontri, Akarin Nimmannit, Suthinee Ithimakin   +5 more
doaj   +1 more source

First-line therapy in HER2 positive metastatic breast cancer. Is the mosaic fully completed or are we missing additional pieces? [PDF]

, 2016
The discovery of human epidermal growth factor receptor 2 (HER2) and its role in the biology of breast cancer and the subsequent development of HER2-targeted therapies, have dramatically improved clinical outcomes for women with early-stage and advanced ...
Cognetti F., Fabi A., Malaguti P., Vari S.   +3 more
core   +2 more sources

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

Molecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni, Antonella Palmese, Stefano Scalera, Laura Cipriani, Davide Mascolo, Patrizia Vici, Teresa Arcuri, Lorena Filomeno, Eriseld Krasniqi, Giovanni Blandino, Giulia Bon, Marcello Maugeri‐Saccà   +11 more
wiley   +1 more source